Similar articles

• Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.

  Richardson MW, Grewal SS. Richardson MW, et al. Pediatr Blood Cancer. 2008 Jan;50(1):186. doi: 10.1002/pbc.21217. Pediatr Blood Cancer. 2008. PMID: 17455313 No abstract available.
• CML: imatinib mesylate (Glivec) or something else?

  Ghosh A. Ghosh A. Nepal Med Coll J. 2007 Dec;9(4):292. Nepal Med Coll J. 2007. PMID: 18298026 No abstract available.
• Imatinib and chronic-phase leukemias.

  Boros LG, Lee WN, Cascante M. Boros LG, et al. N Engl J Med. 2002 Jul 4;347(1):67-8. doi: 10.1056/NEJM200207043470116. N Engl J Med. 2002. PMID: 12097546 No abstract available.
• Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.

  Druker BJ. Druker BJ. Oncogene. 2002 Dec 9;21(56):8541-6. doi: 10.1038/sj.onc.1206081. Oncogene. 2002. PMID: 12476300 Review. No abstract available.
• Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

  Walz C, Sattler M. Walz C, et al. Crit Rev Oncol Hematol. 2006 Feb;57(2):145-64. doi: 10.1016/j.critrevonc.2005.06.007. Epub 2005 Oct 5. Crit Rev Oncol Hematol. 2006. PMID: 16213151 Review.